The legacy success of sildenafil has undeniably shaped the healthcare landscape. However, investing in companies heavily dependent on biosimilars and the waning patent protection surrounding this blockbuster medication presents a notable degree of risk . While leading pharma firms may still realize gains from related therapies , the overall outlook

A thorough sector review is essential for understanding the current dynamics at work. This investigation delves into principal elements influencing the competitive arena, from developing technologies and evolving consumer tastes to legal obstacles and economic risks. We’ll evaluate the overall perspective, including potential expansion areas, ris